MGN 1404

Drug Profile

MGN 1404

Alternative Names: MGN-1404

Latest Information Update: 29 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mologen
  • Developer Charite of Berlin; Max-Delbruck Centre for Molecular Medicine; Mologen
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 09 Jun 2016 Discontinued - Phase-I for Malignant melanoma in Germany (Intratumoural)
  • 18 Oct 2013 Phase-I clinical trials in Malignant melanoma in Germany (Intratumoural)
  • 15 Apr 2013 The Paul-Ehrlich Institute grants approval for a phase I trial in Malignant melanoma in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top